Related Experiment Video
Updated: Dec 6, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.3K
Risdiplam: First Approval
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|October 12, 2020
Summary
Risdiplam (Evrysdi™) is an oral RNA splicing modifier for spinal muscular atrophy. It targets SMN2 to increase functional SMN protein, receiving FDA approval for patients aged two months and older.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Spinal muscular atrophy (SMA) is a rare genetic disorder caused by mutations in the SMN1 gene, leading to a deficiency in survival motor neuron (SMN) protein.
- SMA results in progressive muscle weakness and atrophy, significantly impacting motor function.
- Current treatments aim to address the underlying SMN protein deficiency.
Purpose of the Study:
- To summarize the key milestones in the development of risdiplam (Evrysdi™).
- To highlight the drug's mechanism of action as an SMN2-directed RNA splicing modifier.
- To document the regulatory journey leading to the first approval of risdiplam for SMA treatment.
Main Methods:
- Review of preclinical and clinical development data for risdiplam.
- Analysis of the drug's RNA splicing modification mechanism targeting SMN2.
- Chronological summary of regulatory submissions and approvals.
Main Results:
- Risdiplam is an orally administered small molecule designed to treat SMA.
- It effectively modifies SMN2 splicing to increase functional SMN protein levels.
- Evrysdi™ (risdiplam) received US FDA approval in August 2020 for SMA patients aged 2 months and older.
Conclusions:
- Risdiplam represents a significant advancement in SMA therapeutics.
- Its oral administration and targeted mechanism offer a new treatment option for SMA patients.
- The drug's development highlights progress in genetic medicine and RNA-based therapies.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
106
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
106
01:28Drug Products: Biologics, Biosimilars and Interchangeables
145
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
145
01:25Drug Regulation
2.5K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.5K
01:26Drug Administration and Therapy Phases: Overview
1.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.0K
01:29Drug Delivery: Parenteral Route
1.3K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.3K
01:11Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K